Home > Boards > US Listed > Medical - Drugs > Cerus Corporation (CERS)

I ran a 10-year chart on $CERS to

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mdimport Member Profile
 
Followed By 177
Posts 18,578
Boards Moderated 1
Alias Born 03/21/10
160x600 placeholder
Cerus Corporation to Participate in Upcoming Virtual Investor Conferences Business Wire - 9/9/2020 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/8/2020 5:58:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/1/2020 5:47:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:54:35 PM
Cerus INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch Business Wire - 8/7/2020 8:30:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/5/2020 6:07:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/5/2020 6:04:44 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 4:09:31 PM
Cerus Corporation Announces Record Second Quarter 2020 Results Business Wire - 8/4/2020 4:02:00 PM
Cerus Corp. Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems Business Wire - 7/30/2020 8:30:00 AM
Cerus Corporation to Release Second Quarter 2020 Financial Results on August 4, 2020 Business Wire - 7/23/2020 8:30:00 AM
Cerus Corporation Reports Successful Inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma Business Wire - 7/7/2020 8:30:00 AM
Cerus Corporation Celebrates World Blood Donor Day Business Wire - 6/12/2020 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/9/2020 7:55:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/8/2020 4:18:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2020 7:04:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2020 7:02:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2020 7:00:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2020 6:56:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2020 6:51:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2020 6:48:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2020 6:44:22 PM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/29/2020 4:05:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/28/2020 4:10:02 PM
Cerus Corporation Announces FDA PMA Supplement Submission for Pathogen-Reduced Cryoprecipitated Fibrinogen Complex Business Wire - 5/26/2020 8:30:00 AM
mdimport   Friday, 05/26/17 10:07:32 AM
Re: kevinraugust25 post# 298
Post # of 324 
I ran a 10-year chart on $CERS to find the bottom from a technical perspective: $0.60 on March 1, 2009.



Something doesn't gel with the commentary in the 8-k:

"...On May 23, 2017, Cerus Corporation (the "Company" or "Cerus") announced that it had received notification last week of a pending U.S. supply shortage of a platelet additive solution ("PAS") manufactured and sold by Fresenius Kabi Deutschland GmbH ("Fresenius Kabi"). The pending shortage is due to an unanticipated delay in U.S. Food and Drug Administration ("FDA") approval of a plastic component used in the manufacture of the PAS container following discontinuation of the original component by Fresenius Kabi's supplier. The shortage is expected to temporarily impact certain U.S. blood centers that utilize PAS to produce INTERCEPT platelets. Fresenius Kabi has stated that it is working with its suppliers and the FDA to resolve this delay and minimize any long-term disruption in supply. However, Cerus believes that the pending shortage could adversely affect INTERCEPT platelet production by impacted blood centers through year end. ..."

$CERS price decline also doesn't match the relatively small projected revenue declines: 4-12% depending on actuals.

"...As a result of the expected impact of the PAS supply disruption on INTERCEPT platelet production, the Company is updating its 2017 product revenue guidance to a range of $38 million to $46 million compared to the prior range of $43 million to $48 million. ..."

The paradox of iHub: buy high, sell low
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences